MBX Biosciences, Inc.

Advancing potential breakthrough medicines for endocrine diseases of substantial medical need.

Add To Watchlist
General Information
Company Name
MBX Biosciences, Inc.
Founded Year
2019
Location (Offices)
Carmel, United States +1
Founders / Decision Makers
Greg Davis - Vice President, Product Development Salomon Azoulay - Chief Medical Officer Michelle Graham - Chief Human Resources Officer P. Kent Hawryluk - President & CEO Tim Knickerbocker - COO and co-founder James M. Cornelius - board of directors Steven Prestrelski - Chief Scientific Officer
Number of Employees
50
Industries
Biotechnology, Health Care, Health and Wellness
Funding Stage
Series B
Social Media

MBX Biosciences, Inc. - Company Profile

MBX Biosciences, Inc. is a clinical stage biopharmaceutical company with a focus on Precision Endocrine Peptides (PEPs™) for treating endocrine diseases. Their lead candidate, MBX 2109, is currently in Phase 1 clinical trials for hypoparathyroidism. What sets MBX apart is its leadership team, with members who have collaborated on successful endocrine therapeutics such as Forteo® and Humalog®. The company is backed by prominent investors including Frazier Life Sciences, New Enterprise Associates, and OrbiMed. Having raised $115.00M in their Series B funding round on November 14, 2022, MBX Biosciences is well-positioned to advance their pipeline and address substantial unmet medical needs in endocrine disorders.

Taxonomy: biopharmaceutical company, precision endocrine peptides, clinical stage, hypoparathyroidism, endocrine disorders, pharmaceutical, drug development, clinical trials, investors, life sciences, medical research, leadership team, endocrine therapeutics

Funding Rounds & Investors of MBX Biosciences, Inc. (3)

View All
Funding Stage Amount No. Investors Investors Date
Series B $115.00M 6
New Enterprise Associates, investor in MBX Biosciences, Inc.'s Series B round Norwest Venture Partners, investor in MBX Biosciences, Inc.'s Series B round RA Capital Management, investor in MBX Biosciences, Inc.'s Series B round OrbiMed, investor in MBX Biosciences, Inc.'s Series B round Wellington Management, investor in MBX Biosciences, Inc.'s Series B round Frazier Life Sciences, investor in MBX Biosciences, Inc.'s Series B round
14 Nov 2022
Series A $34.60M 4
New Enterprise Associates, investor in MBX Biosciences, Inc.'s Series A round Frazier Healthcare Partners, investor in MBX Biosciences, Inc.'s Series A round OrbiMed, investor in MBX Biosciences, Inc.'s Series A round Twilight Venture Partners, investor in MBX Biosciences, Inc.'s Series A round
27 Jul 2020
Debt Financing $25.30M - 25 Apr 2019

Latest News of MBX Biosciences, Inc.

View All

No recent news or press coverage available for MBX Biosciences, Inc..

Similar Companies to MBX Biosciences, Inc.

View All
Spruce Biosciences - Similar company to MBX Biosciences, Inc.
Spruce Biosciences Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders
Crinetics Pharmaceuticals - Similar company to MBX Biosciences, Inc.
Crinetics Pharmaceuticals Discovering drugs for endocrine diseases and endocrine-related tumors. #acromegaly #crinetics #CarcinoidSyndrome
Viking Therapeutics, Inc. - Similar company to MBX Biosciences, Inc.
Viking Therapeutics, Inc.
Delphi Diagnostics Inc. - Similar company to MBX Biosciences, Inc.
Delphi Diagnostics Inc. Innovative, unique tests to guide therapy decisions for breast cancer patients.
LEVY Health - Similar company to MBX Biosciences, Inc.
LEVY Health Empowering Providers, Building Families.
Circle Decoration Circle Decoration

Want to dive deeper into MBX Biosciences, Inc.? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now